The impressive 2007 sales growth of cancer drug Nexavar, which increased 125 percent over the year before, was overshadowed by the early termination of an ongoing Phase III study of the drug in non-small-cell lung cancer (NSCLC) due to lack of efficacy, news that sent shares of Onyx Pharmaceuticals Inc. falling 26.4 percent. (BioWorld Today)
The impressive 2007 sales growth of cancer drug Nexavar, which increased 125 percent over the year before, was overshadowed by the early termination of an ongoing Phase III study of the drug in non-small-cell lung cancer (NSCLC) due to lack of efficacy, news that sent shares of Onyx Pharmaceuticals Inc. falling 26.4 percent. (BioWorld Today)
Alleging a "course of anticompetitive conduct," the Federal Trade Commission filed a complaint against Cephalon Inc. regarding deals signed two years ago between the firm and four generic manufacturers to keep lower-cost generic versions of its flagship narcolepsy drug, Provigil, from reaching the market until 2012. (BioWorld Today)
Alleging a "course of anticompetitive conduct," the Federal Trade Commission filed a complaint against Cephalon Inc. regarding deals signed two years ago between the firm and four generic manufacturers to keep lower-cost generic versions of its flagship narcolepsy drug, Provigil, from reaching the market until 2012. (BioWorld Today)
While it awaits results from a confirmatory trial with hereditary angioedema drug DX-88, Cambridge, Mass.-based Dyax Corp. picked up another partner for its antibody platform, signing Sanofi-Aventis in a potential $500 million deal. (BioWorld Today)
While it awaits results from a confirmatory trial with hereditary angioedema drug DX-88, Cambridge, Mass.-based Dyax Corp. picked up another partner for its antibody platform, signing Sanofi-Aventis in a potential $500 million deal. (BioWorld Today)
